DrugDashboards

Clocortolone Pivalate

Clocortolone Pivalate · CLOCORTOLONE PIVALATE .001 g/g · Cream · Topical · Sun Pharmaceutical Industries, Inc.

NDC 51672-4166-06 · 1 TUBE in 1 CARTON / 45 g in 1 TUBE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has jumped 69% in a year, to $5.21 per gram — sharp rises like this often mean supply is already tightening. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$5.21per GMinvoice-surveyed acquisition cost · Jul 23, 2025
  • Part D plans paid (avg)$4.53per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$4.93per unitnegotiated price across 225 plans — before rebates · Apr 1, 2026
  • Federal contracts pay (FSS)$128.06per package of 45GMGolden State Medical Supply, Inc. · Jun 16, 2024

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$4.93per unit
middle half $3.96$5.53 · 225 plans · Apr 1, 2026
Est. net of rebates
≈ $4.93
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
4%of plans cover it
tier 4 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 6 quarters since 2024.

NADAC price per unit

$0$2.00$4.00$6.00Nov 2022Jul 2025$5.21
18 price points · per GM · last surveyed Jul 23, 2025Source: CMS NADAC

Estimated fill cost

WAC per package, as filed
$268.72
Reported to Texas DSHS · 2026 annual filing · Taro

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$14,962
66 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

Regulatory

Application
ANDA206370
TE code
AB
Approval date
Apr 21, 2020
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Clocortolone Pivalate (Cream)

LabelerStrengthFirst seenLast seen
Sun Pharmaceutical Industries, Inc.CLOCORTOLONE PIVALATE .001 g/gJul 16, 2026Sep 3, 2026
Taro Pharmaceuticals U.S.A., inc.CLOCORTOLONE PIVALATE .001 g/gJul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Clocortolone Pivalate — NDC 51672-4166-06," retrieved September 3, 2026, https://drugdashboards.com/drug/51672416606.

Free to cite with attribution — see how the data is put together.